{"filing":{"accession_number":"0001213900-26-111207","cik":"0001711754","ticker":"INMB","company_name":"Inmune Bio, Inc.","form":"8-K","filing_date":"2026-10-21","report_date":"2026-10-21","primary_document":"ea0309223-8k_inmune.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026111207/ea0309223-8k_inmune.htm"},"events":[{"id":36642,"run_id":33787,"accession_number":"0001213900-26-111207","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"INmune Bio entered into a Master Services Agreement with Uniphar establishing a global commercialization framework for Ebstrocel™ in European and MENA markets via named-patient access, and accelerated regulatory timelines with a final pre-MAA package submitted to UK MHRA targeting potential UK approval in mid-2027 and U.S. BLA submission in Q2 2027.","company_name":"Inmune Bio, Inc.","ticker":"INMB","filing_date":"2026-10-21","form":"8-K","submitted_at":null,"items":[{"id":41120,"accession_number":"0001213900-26-111207","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"INmune Bio disclosed two significant operational developments: (1) a Master Services Agreement with Uniphar establishing a global commercialization framework for Ebstrocel™ in European and MENA markets via named-patient access, and (2) acceleration of regulatory timelines with a final pre-MAA package submitted to UK MHRA and a revised strategy targeting potential UK approval in mid-2027 and U.S. BLA submission in Q2 2027. These are material strategic and regulatory milestones for a late-stage biotech company advancing toward commercialization, but they do not fit neatly into the specific event categories (not an earnings release, M\u0026A, debt issuance, or other defined types). The disclosures center on product development progress, regulatory pathway advancement, and commercial partnership execution—core operational matters for a clinical-stage company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-21T13:02:43.161878+00:00","company_name":"","ticker":null,"filing_date":""},{"id":41121,"accession_number":"0001213900-26-111207","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses two material operational milestones for Ebstrocel™: (1) entry into a Master Services Agreement with Uniphar establishing a scalable commercialization framework for international distribution and named-patient access, and (2) submission of a pre-MAA package to the UK MHRA with an accelerated regulatory timeline targeting potential UK approval in mid-2027. These represent significant progress toward commercialization and regulatory approval of a late-stage product candidate, affecting investor assessment of the company's near-term value creation prospects. While not fitting neatly into predefined categories like M\u0026A or debt issuance, these operational and regulatory developments are clearly material to a reasonable investor evaluating the company's pipeline advancement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-21T13:02:43.161878+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":41120,"accession_number":"0001213900-26-111207","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"INmune Bio disclosed two significant operational developments: (1) a Master Services Agreement with Uniphar establishing a global commercialization framework for Ebstrocel™ in European and MENA markets via named-patient access, and (2) acceleration of regulatory timelines with a final pre-MAA package submitted to UK MHRA and a revised strategy targeting potential UK approval in mid-2027 and U.S. BLA submission in Q2 2027. These are material strategic and regulatory milestones for a late-stage biotech company advancing toward commercialization, but they do not fit neatly into the specific event categories (not an earnings release, M\u0026A, debt issuance, or other defined types). The disclosures center on product development progress, regulatory pathway advancement, and commercial partnership execution—core operational matters for a clinical-stage company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-21T13:02:43.161878+00:00","company_name":"Inmune Bio, Inc.","ticker":"INMB","filing_date":"2026-10-21"},{"id":41121,"accession_number":"0001213900-26-111207","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses two material operational milestones for Ebstrocel™: (1) entry into a Master Services Agreement with Uniphar establishing a scalable commercialization framework for international distribution and named-patient access, and (2) submission of a pre-MAA package to the UK MHRA with an accelerated regulatory timeline targeting potential UK approval in mid-2027. These represent significant progress toward commercialization and regulatory approval of a late-stage product candidate, affecting investor assessment of the company's near-term value creation prospects. While not fitting neatly into predefined categories like M\u0026A or debt issuance, these operational and regulatory developments are clearly material to a reasonable investor evaluating the company's pipeline advancement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-21T13:02:43.161878+00:00","company_name":"Inmune Bio, Inc.","ticker":"INMB","filing_date":"2026-10-21"}]}